Merck says still plans Cubist purchase, despite patent setback

(Reuters) – Merck & Co on Tuesday said it will proceed with its planned $8.4 billion (5.3 billion pounds) purchase of Cubist Pharmaceuticals and still expects the deal to boost its long-term earnings, despite a court ruling that could speed the arrival of generic forms of Cubist’s top-selling product.

Link to article:


Leave a Reply

Your email address will not be published. Required fields are marked *